대한약학회 추계총회 및 학술대회 (2015년) Development of a protocol synopsis of salirasib+FOLFIRI versus placebo+FOLFIRI as secondline treatment in KRAS mutant mCRC patients after failure of prior FOLFOX treatment

학술대회자료

Development of a protocol synopsis of salirasib+FOLFIRI versus placebo+FOLFIRI as secondline treatment in KRAS mutant mCRC patients after failure of prior FOLFOX treatment

대한약학회
추계총회 및 학술대회
(2015년)
2015.10

163 - 163 (1 pages)

커버이미지 없음

원문보기

원문저장

Development of a protocol synopsis of salirasib+FOLFIRI versus placebo+FOLFIRI as secondline treatment in KRAS mutant mCRC patients after failure of prior FOLFOX treatment

(0)

(0)

(0)

(0)

Development of a protocol synopsis of salirasib+FOLFIRI versus placebo+FOLFIRI as secondline treatment in KRAS mutant mCRC patients after failure of prior FOLFOX treatment

(0)

(0) 팝업 열기 팝업 닫기

(0)

(0)

(0)